Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women \> 18 years~* Subjects with chronic plaque psoriasis stable for at least 3 months and moderate to severe for at least 6 months~* Subjects with Psoriasis Area and Severity Index (PASI) ≥ 12 and Body Surface Area (BSA) ≥ 10 %~* Subjects were candidates for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy~Exclusion Criteria:~* Subjects with an erythrodermic, guttate, palmar or plantar, generalized pustular form of psoriasis~* A history of chronic infection, recent serious or life-threatening infection (within six months, including herpes zoster), or any current sign or symptom that may indicate an infection (e.g. fever, cough);~* White blood cell counts less than 4000/mm\^3 or more than 20000/mm\^3~* Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis)~* Systemic Lupus~* Non respect of adequate wash out periods for treatments that might have an impact on the disease~* Any associated disease that could be impacted by the study treatment intake~* Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous injections of Placebo every 2 weeks
- Certolizumab Pegol 200 mg (Type: EXPERIMENTAL): Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter
- Certolizumab Pegol 400 mg (Type: EXPERIMENTAL): Subcutaneous injections of 400 mg every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).